High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

Abstract

These data continue to support the notion that high-dose IL-2 produces durable responses in some patients with metastatic melanoma and should be considered a therapeutic option for appropriately selected patients with this disease.